CD133 (also known as prominin-1) is a cell surface glycoprotein that is widely used for the identification of stem cells. Furthermore, its glycosylated epitope, AC133, has recently been discussed as a marker of cancer stem cells in various human malignancies. During our recent experiments on rhabdomyosarcomas (RMS), we unexpectedly identified an atypical nuclear localization of CD133 in a relatively stable subset of cells in five RMS cell lines established in our laboratory. To the best of our knowledge, this atypical localization of CD133 has not yet been proven or analyzed in detail in cancer cells. In the present study, we verified the nuclear localization of CD133 in RMS cells using three independent anti-CD133 antibodies, including both rabbit polyclonal and mouse monoclonal antibodies. Indirect immunofluorescence and confocal microscopy followed by software cross-section analysis, transmission electron microscopy and cell fractionation with immunoblotting were also employed, and all the results undeniably confirmed the presence of CD133 in the nuclei of stable minor subpopulations of all five RMS cell lines. The proportion of cells showing an exclusive nuclear localization of CD133 ranged from 3.4 to 7.5%, with only minor differences observed among the individual anti-CD133 antibodies. Although the role of CD133 in the cell nucleus remains unclear, these results clearly indicate that this atypical nuclear localization of CD133 in a minor subpopulation of cancer cells is a common phenomenon in RMS cell lines.

Department of Experimental Biology Faculty of Science Masaryk University 61137 Brno Czech Republic

Department of Histology and Embryology Faculty of Medicine Masaryk University 61137 Brno Czech Republic

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute 61137 Brno Czech Republic

Zobrazit více v PubMed

Corbeil D, Karbanová J, Fargeas CA, Jászai J. Prominin-1 (CD133): Molecular and cellular features across species. Adv Exp Med Biol. 2013;777:3–24. doi: 10.1007/978-1-4614-5894-4_1. PubMed DOI

Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-Schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: Limitations, problems and challenges. J Pathol. 2013;229:355–378. doi: 10.1002/path.4086. PubMed DOI

Friedman GK, Gillespie GY. Cancer stem cells and pediatric solid tumors. Cancers (Basel) 2011;3:298–318. doi: 10.3390/cancers3010298. PubMed DOI PMC

Xia P. Surface markers of cancer stem cells in solid tumors. Curr Stem Cell Res Ther. 2014;9:102–111. doi: 10.2174/1574888X09666131217003709. PubMed DOI

Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K, Zitterbart K, Sterba J. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer. 2008;8:300. doi: 10.1186/1471-2407-8-300. PubMed DOI PMC

Sana J, Zambo I, Skoda J, Neradil J, Chlapek P, Hermanova M, Mudry P, Vasikova A, Zitterbart K, Hampl A, et al. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal Cell Pathol (Amst) 2011;34:303–318. doi: 10.1155/2011/939457. PubMed DOI PMC

Di Fiore R, Santulli A, Ferrante RD, Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere G, Vento R. Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol. 2009;219:301–313. doi: 10.1002/jcp.21667. PubMed DOI

Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Pirozzi G, Papaccio G. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 2011;25:2022–2030. doi: 10.1096/fj.10-179036. PubMed DOI

Walter D, Satheesha S, Albrecht P, Bornhauser BC, D’Alessandro V, Oesch SM, Rehrauer H, Leuschner I, Koscielniak E, Gengler C, et al. CWS Study Group: CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One. 2011;6:e19506. doi: 10.1371/journal.pone.0019506. PubMed DOI PMC

Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY, Friedman GK. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer. 2013;60:45–52. doi: 10.1002/pbc.24117. PubMed DOI PMC

Veselska R, Skoda J, Neradil J. Detection of cancer stem cell markers in sarcomas. Klin Onkol. 2012;25:2S16–2S20. PubMed

Dela Cruz FS. Cancer stem cells in pediatric sarcomas. Front Oncol. 2013;3:168. doi: 10.3389/fonc.2013.00168. PubMed DOI PMC

Satheesha S, Schafer BW. Cancer stem cells in pediatric sarcomas. In: Hayat MA, editor. Stem Cells and Cancer Stem Cells. Springer; Dordrecht: 2014. pp. 111–126. DOI

Cantile M, Collina F, D’Aiuto M, Rinaldo M, Pirozzi G, Borsellino C, Franco R, Botti G, Di Bonito M. Nuclear localization of cancer stem cell marker CD133 in triple-negative breast cancer: A case report. Tumori. 2013;99:e245–e250. PubMed

Huang M, Zhu H, Feng J, Ni S, Huang J. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer. Dis Markers. 2015;2015:986095. doi: 10.1155/2015/986095. PubMed DOI PMC

Veselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T, Relichova J. Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer. 2006;6:32. doi: 10.1186/1471-2407-6-32. PubMed DOI PMC

Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med Berl. 2008;86:1025–1032. doi: 10.1007/s00109-008-0357-8. PubMed DOI PMC

Loja T, Chlapek P, Kuglik P, Pesakova M, Oltova A, Cejpek P, Veselska R. Characterization of a GM7 glioblastoma cell line showing CD133 positivity and both cytoplasmic and nuclear localization of nestin. Oncol Rep. 2009;21:119–127. PubMed

Tirino V, Desiderio V, d’Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One. 2008;3:e3469. doi: 10.1371/journal.pone.0003469. PubMed DOI PMC

Mak AB, Nixon AM, Kittanakom S, Stewart JM, Chen GI, Curak J, Gingras AC, Mazitschek R, Neel BG, Stagljar I, Moffat J. Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep. 2012;2:951–963. doi: 10.1016/j.celrep.2012.09.016. PubMed DOI PMC

Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 2009;15:6484–6489. doi: 10.1158/1078-0432.CCR-08-2813. PubMed DOI PMC

Mills IG. Nuclear translocation and functions of growth factor receptors. Semin Cell Dev Biol. 2012;23:165–171. doi: 10.1016/j.semcdb.2011.09.004. PubMed DOI

Carpenter G, Liao HJ. Receptor tyrosine kinases in the nucleus. Cold Spring Harb Perspect Biol. 2013;5:a008979. doi: 10.1101/cshperspect.a008979. PubMed DOI PMC

Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M, Nakagawara A, Kamijo T. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene. 2011;30:97–105. doi: 10.1038/onc.2010.383. PubMed DOI

Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y, et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci USA. 2013;110:6829–6834. doi: 10.1073/pnas.1217002110. PubMed DOI PMC

Shimozato O, Waraya M, Nakashima K, Souda H, Takiguchi N, Yamamoto H, Takenobu H, Uehara H, Ikeda E, Matsushita S, et al. Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation. Oncogene. 2014;34:1949–1960. doi: 10.1038/onc.2014.141. PubMed DOI

Emerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease

Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells

Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma

Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice